Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinic Acid as Add-on Therapy for Migraine Prophylaxis
NCT05846373Phase 2Completed
- Sponsor
- Bangabandhu Sheikh Mujib Medical University
- Start
- Nov 2022
- Primary completion
- Jan 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of niacin in migraine (3 arms), sponsored by Bangabandhu Sheikh Mujib Medical University. Primary endpoint: Migraine days per 4 weeks at 12 weeks. Started Nov 2022; status: completed.
02
Drugs
niacin
03
Conditions
migraine
Beyond the preview
Go deeper on NCT05846373.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05846373.